Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity

World Journal of Gastroenterology

Volumn 24, Issue 15, 2018, Pages 1601-1615

  Pirola, Carlos J ^a,b   Sookoian, Silvia ^a,b  

^a INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Fibrosis; Genetics; Liver biopsy; Metabolomics; MiR122; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; PNPLA3; Proteomics; TM6SF2; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER; CELL FREE DNA; CELL FREE NUCLEIC ACID; CIRCULATING MICRORNA; DNA; PROTEIN; UNCLASSIFIED DRUG;

DATA PROCESSING; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; EPIGENETICS; GENETIC MARKER; GENOMICS; HUMAN; LIVER CANCER; METABOLOMICS; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PREDICTION; PROTEOMICS; REVIEW; RISK ASSESSMENT; TRANSCRIPTOMICS; WHOLE GENOME SEQUENCING; BIOPSY; BLOOD; DISEASE EXACERBATION; GENETICS; LIVER; PATHOLOGY; PROCEDURES; RISK FACTOR; SEVERITY OF ILLNESS INDEX; WHOLE EXOME SEQUENCING;

BIOMARKERS; BIOPSY; CIRCULATING MICRORNA; DISEASE PROGRESSION; HUMANS; LIVER; METABOLOMICS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; WHOLE EXOME SEQUENCING;

EID: 85045845276     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v24.i15.1601     Document Type: Review

References (74)

1. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1: 15080 [PMID: 27188459 DOI: 10.1038/nrdp.2015.80]
2. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67: 328-357 [PMID: 28714183 DOI: 10.1002/ hep.29367]
3. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009;13: 533-544 [PMID: 19818303 DOI: 10.1016/ j.cld.2009.07.008]
4. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7: 195-203 [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21]
5. Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease and metabolic syndrome: Shared genetic basis of pathogenesis. Hepatology 2016;64: 1417-1420 [PMID: 27480050 DOI: 10.1002/ hep.28746]
6. Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol 2017;23: 1-12 [PMID: 28268262 DOI: 10.3350/cmh.2016.0109]
7. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ ng.257]
8. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50: 2111-2116 [PMID: 19738004 DOI: 10.1194/jlr. P900013-JLR200]
9. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
10. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, Vogt TF, Hobbs HH, Cohen JC. Exomewide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46: 352-356 [PMID: 24531328 DOI: 10.1038/ng.2901]
11. Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2- rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology 2015;62: 1742-1756 [PMID: 26331730 DOI: 10.1002/ hep.28142]
12. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Käkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61: 506-514 [PMID: 25251399 DOI: 10.1002/hep.27490]
13. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014;5: 4309 [PMID: 24978903 DOI: 10.1038/ncomms5309]
14. Sookoian S, Pirola CJ. Liver enzymes, metabolomics and genomewide association studies: from systems biology to the personalized medicine. World J Gastroenterol 2015;21: 711-725 [PMID: 25624707 DOI: 10.3748/wjg.v21.i3.711]
15. Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL, San Martino J, Pirola CJ. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015;61: 515-525 [PMID: 25302781 DOI: 10.1002/ hep.27556]
16. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137: 865-872 [PMID: 19524579 DOI: 10.1053/j.gastro.2009.06.005]
17. Nobili V, Donati B, Panera N, Vongsakulyanon A, Alisi A, Dallapiccola B, Valenti L. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014;58: 632-636 [PMID: 24345846 DOI: 10.1097/MPG.0000000000000279]
18. Zhou Y, Orešič M, Leivonen M, Gopalacharyulu P, Hyysalo J, Arola J, Verrijken A, Francque S, Van Gaal L, Hyötyläinen T, Yki- Järvinen H. Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. Clin Gastroenterol Hepatol 2016;14: 1463-1472. e6 [PMID: 27317851 DOI: 10.1016/j.cgh.2016.05.046]
19. Sevastianova K, Kotronen A, Gastaldelli A, Perttilä J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrannini E, Rissanen A, Olkkonen VM, Yki-Järvinen H. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011;94: 104-111 [PMID: 21525193 DOI: 10.3945/ajcn.111.012369]
20. Shen J, Wong GL, Chan HL, Chan RS, Chan HY, Chu WC, Cheung BH, Yeung DK, Li LS, Sea MM, Woo J, Wong VW. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2015;30: 139-146 [PMID: 25040896 DOI: 10.1111/jgh.12656]
21. Krawczyk M, Jiménez-Agüero R, Alustiza JM, Emparanza JI, Perugorria MJ, Bujanda L, Lammert F, Banales JM. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis 2016;12: 1838-1846 [PMID: 27576208 DOI: 10.1016/j.soard.2016.06.004]
22. Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, Martino JS, Castaño GO, Pirola CJ. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol 2016;240: 437-449 [PMID: 27577682 DOI: 10.1002/path.4803]
23. Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology 2010;52: 1992-2000 [PMID: 20890895 DOI: 10.1002/hep.23927]
24. Ahrens M, Ammerpohl O, von Schönfels W, Kolarova J, Bens S, Itzel T, Teufel A, Herrmann A, Brosch M, Hinrichsen H, Erhart W, Egberts J, Sipos B, Schreiber S, Häsler R, Stickel F, Becker T, Krawczak M, Röcken C, Siebert R, Schafmayer C, Hampe J. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013;18: 296-302 [PMID: 23931760 DOI: 10.1016/j.cmet.2013.07.004]
25. Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, Hyrich KL, Wilson AG, Morgan AW, Isaacs JD, Worthington J, Barton A. Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 2016;68: 1353-1360 [PMID: 26814849 DOI: 10.1002/art.39590]
26. Zhang X, Biagini Myers JM, Yadagiri VK, Ulm A, Chen X, Weirauch MT, Khurana Hershey GK, Ji H. Nasal DNA methylation differentiates corticosteroid treatment response in pediatric asthma: A pilot study. PLoS One 2017;12: e0186150 [PMID: 29028809 DOI: 10.1371/journal.pone.0186150]
27. Roberts S, Lester KJ, Hudson JL, Rapee RM, Creswell C, Cooper PJ, Thirlwall KJ, Coleman JR, Breen G, Wong CC, Eley TC. Serotonin transporter [corrected] methylation and response to cognitive behaviour therapy in children with anxiety disorders. Transl Psychiatry 2014;4: e444 [PMID: 25226553 DOI: 10.1038/ tp.2014.109]
28. Shock LS, Thakkar PV, Peterson EJ, Moran RG, Taylor SM. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc Natl Acad Sci U S A 2011;108: 3630-3635 [PMID: 21321201 DOI: 10.1073/ pnas.1012311108]
29. Pirola CJ, Gianotti TF, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, Martino JS, Castaño GO, Sookoian S. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013;62: 1356-1363 [PMID: 22879518 DOI: 10.1136/gutjnl-2012-302962]
30. MANDEL P, METAIS P. [Not Available]. C R Seances Soc Biol Fil 1948;142: 241-243 [PMID: 18875018]
31. Hardy T, Zeybel M, Day CP, Dipper C, Masson S, McPherson S, Henderson E, Tiniakos D, White S, French J, Mann DA, Anstee QM, Mann J. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 2017;66: 1321-1328 [PMID: 27002005 DOI: 10.1136/ gutjnl-2016-311526]
32. Yiǧit B, Boyle M, Özler O, Erden N, Tutucu F, Hardy T, Bergmann C, Distler JHW, Adali G, Dayangaç M, Mann DA, Zeybel M, Mann J. Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis. Gut 2018; Epub ahead of print [PMID: 29353249 DOI: 10.1136/gutjnl-2017-315668]
33. Sookoian S, Pirola CJ. Cell-free DNA methylation as liquid biopsy for the assessment of fibrosis in patients with nonalcoholic steatohepatitis: a gap between innovation and implementation. Hepatobiliary Surg Nutr 2017;6: 117-121 [PMID: 28503559 DOI: 10.21037/hbsn.2017.01.07]
34. Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One 2015;10: e0142661 [PMID: 26565986 DOI: 10.1371/journal.pone.0142661]
35. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6: e23937 [PMID: 21886843 DOI: 10.1371/journal.pone.0023937]
36. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum noncoding RNAs to liver histology and disease pathogenesis. Gut 2015;64: 800-812 [PMID: 24973316 DOI: 10.1136/gutjnl-2014-306996]
37. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One 2014;9: e105192 [PMID: 25141008 DOI: 10.1371/journal.pone.0105192]
38. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60: 167-174 [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042]
39. Sookoian S, Castaño G, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 2009;42: 624-629 [PMID: 19071103 DOI: 10.1016/j.clinbiochem.2008.11.005]
40. Wood GC, Chu X, Argyropoulos G, Benotti P, Rolston D, Mirshahi T, Petrick A, Gabrielson J, Carey DJ, DiStefano JK, Still CD, Gerhard GS. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep 2017;7: 43238 [PMID: 28266614 DOI: 10.1038/srep43238]
41. Decaris ML, Li KW, Emson CL, Gatmaitan M, Liu S, Wang Y, Nyangau E, Colangelo M, Angel TE, Beysen C, Cui J, Hernandez C, Lazaro L, Brenner DA, Turner SM, Hellerstein MK, Loomba R. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood. Hepatology 2017;65: 78-88 [PMID: 27706836 DOI: 10.1002/hep.28860]
42. Okanoue T, Ebise H, Kai T, Mizuno M, Shima T, Ichihara J, Aoki M. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol 2018;53: 129-139 [PMID: 28589339 DOI: 10.1007/s00535-017-1355-9]
43. Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013;57: 103-111 [PMID: 22930399 DOI: 10.1002/hep.26030]
44. Rodriguez-Suarez E, Mato JM, Elortza F. Proteomics analysis of human nonalcoholic fatty liver. Methods Mol Biol 2012;909: 241-258 [PMID: 22903720 DOI: 10.1007/978-1-61779-959-4-16]
45. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005;42: 665-674 [PMID: 16116632 DOI: 10.1002/hep.20838]
46. Ulukaya E, Yilmaz Y, Moshkovskii S, Karpova M, Pyatnitskiy M, Atug O, Dolar E. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol 2009;44: 1471-1476 [PMID: 19883279 DOI: 10.3109/003655209 03353379]
47. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50: 1827-1838 [PMID: 19937697 DOI: 10.1002/ hep.23229]
48. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, Milburn M. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011;60: 404-413 [PMID: 20423748 DOI: 10.1016/j.metabol.2010.03.006]
49. Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2017; Epub ahead of print [PMID: 28696585]
50. Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavín Trueba JL, Mayo R, Ilisso CP, de Juan VG, Iruarrizaga-Lejarreta M, delaCruz-Villar L, Mincholé I, Robinson A, Crespo J, Martín-Duce A, Romero-Gómez M, Sann H, Platon J, Van Eyk J, Aspichueta P, Noureddin M, Falcón- Pérez JM, Anguita J, Aransay AM, Martínez-Chantar ML, Lu SC, Mato JM. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology 2017;152: 1449-1461.e7 [PMID: 28132890 DOI: 10.1053/j.gastro.2017.01.015]
51. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14: 804-810 [PMID: 22152305 DOI: 10.1016/j.cmet.2011.11.004]
52. Sookoian S, Castaño GO, Scian R, Fernández Gianotti T, Dopazo H, Rohr C, Gaj G, San Martino J, Sevic I, Flichman D, Pirola CJ. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. Am J Clin Nutr 2016;103: 422-434 [PMID: 26791191 DOI: 10.3945/ajcn.115.118695]
53. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, Walter K, Menni C, Chen L, Vasquez L, Valdes AM, Hyde CL, Wang V, Ziemek D, Roberts P, Xi L, Grundberg E; Multiple Tissue Human Expression Resource (MuTHER) Consortium, Waldenberger M, Richards JB, Mohney RP, Milburn MV, John SL, Trimmer J, Theis FJ, Overington JP, Suhre K, Brosnan MJ, Gieger C, Kastenmüller G, Spector TD, Soranzo N. An atlas of genetic influences on human blood metabolites. Nat Genet 2014;46: 543-550 [PMID: 24816252 DOI: 10.1038/ng.2982]
54. Yin X, Subramanian S, Willinger CM, Chen G, Juhasz P, Courchesne P, Chen BH, Li X, Hwang SJ, Fox CS, O'Donnell CJ, Muntendam P, Fuster V, Bobeldijk-Pastorova I, Sookoian SC, Pirola CJ, Gordon N, Adourian A, Larson MG, Levy D. Metabolite Signatures of Metabolic Risk Factors and their Longitudinal Changes. J Clin Endocrinol Metab 2016;101: 1779-1789 [PMID: 26908103 DOI: 10.1210/jc.2015-2555]
55. Sookoian S, Pirola CJ. NAFLD. Metabolic make-up of NASH: from fat and sugar to amino acids. Nat Rev Gastroenterol Hepatol 2014;11: 205-207 [PMID: 24566880 DOI: 10.1038/nrgastro.2014.25]
56. Sookoian S, Pirola CJ. The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function. Hepatology 2018;67: 1177-1178 [PMID: 29205411 DOI: 10.1002/hep.29705]
57. Goffredo M, Santoro N, Tricò D, Giannini C, D'Adamo E, Zhao H, Peng G, Yu X, Lam TT, Pierpont B, Caprio S, Herzog RI. A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9: pii: E642 [PMID: 28640216 DOI: 10.3390/nu9070642]
58. Gaggini M, Carli F, Rosso C, Buzzigoli E, Marietti M, Della Latta V, Ciociaro D, Abate ML, Gambino R, Cassader M, Bugianesi E, Gastaldelli A. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology 2018;67: 145-158 [PMID: 28802074 DOI: 10.1002/hep.29465]
59. Min HK, Sookoian S, Pirola CJ, Cheng J, Mirshahi F, Sanyal AJ. Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2014;307: G66-G76 [PMID: 24763554 DOI: 10.1152/ajpgi.00335.2013]
60. Sookoian S, Puri P, Castaño GO, Scian R, Mirshahi F, Sanyal AJ, Pirola CJ. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. Liver Int 2017;37: 611-619 [PMID: 27614103 DOI: 10.1111/liv.13249]
61. Wanichthanarak K, Fan S, Grapov D, Barupal DK, Fiehn O. Metabox: A Toolbox for Metabolomic Data Analysis, Interpretation and Integrative Exploration. PLoS One 2017;12: e0171046 [PMID: 28141874]
62. Wanichthanarak K, Fahrmann JF, Grapov D. Genomic, Proteomic, and Metabolomic Data Integration Strategies. Biomark Insights 2015;10: 1-6 [PMID: 26396492 DOI: 10.4137/BMI.S29511]
63. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102: 15545-15550 [PMID: 16199517 DOI: 10.1073/pnas.0506580102]
64. Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One 2013;8: e58895 [PMID: 23516571]
65. Cambiaghi A, Ferrario M, Masseroli M. Analysis of metabolomic data: tools, current strategies and future challenges for omics data integration. Brief Bioinform 2017;18: 498-510 [PMID: 27075479]
66. Dumas ME, Kinross J, Nicholson JK. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 2014;146: 46-62 [PMID: 24211299 DOI: 10.1053/j.gastro.2013.11.001]
67. Kamburov A, Cavill R, Ebbels TM, Herwig R, Keun HC. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 2011;27: 2917-2918 [PMID: 21893519 DOI: 10.1093/bioinformatics/btr499]
68. Safaei A, Arefi Oskouie A, Mohebbi SR, Rezaei-Tavirani M, Mahboubi M, Peyvandi M, Okhovatian F, Zamanian-Azodi M. Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench 2016;9: 158-173 [PMID: 27458508]
69. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res 2015;43: W251-W257 [PMID: 25897128 DOI: 10.1093/nar/ gkv380]
70. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. Curr Protoc Bioinformatics 2016;55: 14.10.1-14.10.91 [PMID: 27603023 DOI: 10.1002/cpbi.11]
71. Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012;56: 118-129 [PMID: 22290395 DOI: 10.1002/hep.25630]
72. Sutti S, Jindal A, Bruzzì S, Locatelli I, Bozzola C, Albano E. Is there a role for adaptive immunity in nonalcoholic steatohepatitis? World J Hepatol 2015;7: 1725-1729 [PMID: 26167244 DOI: 10.4254/wjh.v7.i13.1725]
73. Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, Sartor MA, Stringer KA, Jagadish HV, Burant C, Athey B, Omenn GS. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics 2012;28: 373-380 [PMID: 22135418 DOI: 10.1093/bioinformatics/btr661]
74. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13: 2498-2504 [PMID: 14597658 DOI: 10.1101/gr.1239303]